Aclaris Financial Statements From 2010 to 2026

Stocks USA . 
Stock . Aclaris Therapeutics
ACRS Stock  USD 2.63  0.02  0.75%   
Aclaris Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aclaris Therapeutics' valuation are provided below:
Gross Profit
-43.4 M
Market Capitalization
312 M
Enterprise Value Revenue
12.2827
Revenue
15.7 M
Earnings Share
(1.58)
There are over one hundred nineteen available fundamental signals for Aclaris Therapeutics, which can be analyzed over time and compared to other ratios. All traders should validate Aclaris Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 423.2 M in 2026. Enterprise Value is likely to gain to about 374.1 M in 2026

Aclaris Therapeutics Total Revenue

10.9 Million

Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 808 K, Interest Expense of 3.2 M or Selling General Administrative of 21.5 M, as well as many indicators such as Price To Sales Ratio of 11.19, Dividend Yield of 0.0 or PTB Ratio of 1.66. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aclaris Stock
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Aclaris Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets175.4 M253.4 M140.3 M
Slightly volatile
Other Current Liabilities27.8 M26.5 M8.3 M
Slightly volatile
Total Current Liabilities38.2 M36.3 M15.9 M
Slightly volatile
Other Liabilities40.4 M38.5 M13.4 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.2 M1.2 M
Slightly volatile
Accounts Payable6.8 M5.4 M5.1 M
Slightly volatile
Cash47.8 M28.3 M36.8 M
Pretty Stable
Non Current Assets Total114 M108.5 M36.6 M
Slightly volatile
Cash And Short Term Investments132.3 M130.6 M102.7 M
Slightly volatile
Common Stock Shares Outstanding93.3 M88.9 M38.4 M
Slightly volatile
Short Term Investments96.4 M102.4 M74.2 M
Slightly volatile
Liabilities And Stockholders Equity175.4 M253.4 M140.3 M
Slightly volatile
Non Current Liabilities Total23.1 M38.2 M21.3 M
Pretty Stable
Other Current Assets7.3 M13.8 M5.9 M
Slightly volatile
Total Liabilities39 M74.5 M35.8 M
Slightly volatile
Property Plant And Equipment Gross7 M6.7 M2.8 M
Slightly volatile
Total Current Assets139.1 M144.8 M108.3 M
Slightly volatile
Property Plant Equipment1.9 M1.3 M1.3 M
Slightly volatile
Other Assets1.9 M2 M19.6 M
Pretty Stable
Net Receivables521.3 K365.7 K337.8 K
Slightly volatile
Capital Surpluse553.9 M1 B472.6 M
Slightly volatile
Non Current Liabilities Other13.2 M15.1 M8.2 M
Slightly volatile
Short and Long Term Debt Total2.2 M2.3 M3.1 M
Pretty Stable
Capital Lease Obligations594.9 K489.9 K370 K
Slightly volatile
Net Invested Capital129.6 M140 M184.9 M
Slightly volatile
Short and Long Term Debt113.6 K127.8 K139.5 K
Slightly volatile
Net Working Capital102.8 M84.9 M148.7 M
Slightly volatile
Short Term Debt589.7 K1.1 M410.5 K
Slightly volatile
Long Term Debt Total10.8 M9.6 M20.2 M
Slightly volatile
Current Deferred Revenue4.2 M4.5 M8.5 M
Very volatile

Aclaris Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization808 K928 K622.5 K
Slightly volatile
Selling General Administrative21.5 M25.5 M16.9 M
Slightly volatile
Other Operating Expenses194 M184.7 M79.8 M
Slightly volatile
Research Development46.9 M38.6 M35.8 M
Slightly volatile
Total Operating Expenses190.6 M181.5 M76.2 M
Slightly volatile
Interest Income83.2 K93.6 K102.2 K
Slightly volatile
Preferred Stock And Other Adjustments2.1 M2.3 M2.5 M
Slightly volatile
Selling And Marketing Expenses242 K254.7 K4.3 M
Pretty Stable
Reconciled Depreciation1.3 M726.3 K1.1 M
Pretty Stable
Non Recurring14.8 M16.7 M18.2 M
Slightly volatile

Aclaris Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow30 M45.9 M27.1 M
Slightly volatile
Depreciation808 K928 K622.5 K
Slightly volatile
End Period Cash Flow30.5 M28.3 M24.7 M
Slightly volatile
Stock Based Compensation12.9 M12.5 M9.1 M
Slightly volatile
Change To Netincome22 M22.7 M15.5 M
Slightly volatile
Change To Inventory730.5 K695.8 K351.4 K
Slightly volatile
Issuance Of Capital Stock81.8 M86.1 M87.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.1911.78210
Slightly volatile
Days Sales Outstanding6.777.1360.136
Slightly volatile
Stock Based Compensation To Revenue0.630.674.7799
Slightly volatile
Capex To Depreciation0.160.1711.1055
Slightly volatile
EV To Sales9.9110.43150
Slightly volatile
Payables Turnover0.520.540.4797
Slightly volatile
Sales General And Administrative To Revenue1.31.3610.5231
Slightly volatile
Research And Ddevelopement To Revenue1.962.0613.7247
Slightly volatile
Capex To Revenue0.00710.00740.3874
Slightly volatile
Cash Per Share1.611.694.6637
Slightly volatile
Days Payables Outstanding6707054 K
Slightly volatile
Income Quality0.170.1520.7062
Slightly volatile
Intangibles To Total Assets0.00150.00160.0833
Slightly volatile
Net Debt To EBITDA0.460.491.0075
Slightly volatile
Current Ratio4.364.5818.3201
Slightly volatile
Receivables Turnover27.1852.9822.1488
Slightly volatile
Debt To Equity0.01820.01920.0373
Pretty Stable
Capex Per Share0.00170.00180.0239
Slightly volatile
Revenue Per Share0.190.220.1597
Slightly volatile
Interest Debt Per Share0.03670.03870.096
Pretty Stable
Debt To Assets0.01290.01360.0234
Pretty Stable
Days Of Payables Outstanding6707054 K
Slightly volatile
Ebt Per Ebit0.810.840.9882
Pretty Stable
Long Term Debt To Capitalization0.140.20.1625
Slightly volatile
Total Debt To Capitalization0.01790.01890.0301
Pretty Stable
Debt Equity Ratio0.01820.01920.0373
Pretty Stable
Quick Ratio4.364.5818.3675
Slightly volatile
Net Income Per E B T1.211.151.0573
Slightly volatile
Cash Ratio0.850.898.9233
Slightly volatile
Days Of Sales Outstanding6.777.1360.136
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0404
Pretty Stable
Fixed Asset Turnover17.5516.716.9695
Slightly volatile
Debt Ratio0.01290.01360.0234
Pretty Stable
Price Sales Ratio11.1911.78210
Slightly volatile
Asset Turnover0.05650.07650.0439
Slightly volatile
Gross Profit Margin0.80.770.3868
Slightly volatile

Aclaris Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap423.2 M220.5 M393.4 M
Slightly volatile
Enterprise Value374.1 M195.2 M360.4 M
Slightly volatile

Aclaris Fundamental Market Drivers

Aclaris Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.5 M4.2 M
Total Revenue21.5 M10.9 M
Cost Of Revenue3.2 M5.5 M
Stock Based Compensation To Revenue 0.67  0.63 
Sales General And Administrative To Revenue 1.36  1.30 
Research And Ddevelopement To Revenue 2.06  1.96 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.22  0.19 
Ebit Per Revenue(6.82)(7.16)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY